In vitro proliferation of human osteogenic cells in presence of different commercial bone substitute materials combined with enamel matrix derivatives

Table 3 Bonferroni's t-test for AB reduction of osteogenic cells cultivated on the various BSM compared to the untreated control or EMD after 7 d

Comparison	Diff of Means	t	p
control vs. BRE + EMD	1544	14.0	<0.001**
control vs. NBO + EMD	1327	12.0	<0.001**
control vs. BIM + EMD	1206	10.9	<0.001**
control vs. BOC + EMD	1084	9.8	<0.001**
control vs. CBM + EMD	1002	9.1	<0.001**
control vs. EMD	758	6.9	<0.001**
control vs. BIO + EMD	400	3.6	0.015*
control vs. PGL + EMD	54	0.4	>1.0
EMD vs. PGL + EMD	812	7.0	<0.001**
EMD vs. BRE + EMD	786	6.8	<0.001**
EMD vs. NBO + EMD	569	4.9	0.001*
EMD vs. BIM + EMD	448	3.8	0.009*
EMD vs. BIO + EMD	358	3.1	0.048*
EMD vs. BOC + EMD	326	2.8	0.085
EMD vs. CBM + EMD	244	2.1	0.352

(BIO = Bio-Oss^®, NBO = NanoBone^®, BRE = Bioresorb^®, CBM = Cerasorb^® M, PGL = PerioGlas^®, BOC = Straumann^® BoneCeramic, BIM = BONIT^®matrix; t = probability; p = p-value; *significant, ** highly significant).

ISSN: 1746-160X